Analysts Set Aflac Incorporated (NYSE:AFL) PT at $103.36

Aflac Incorporated (NYSE:AFL) has been assigned an average rating of “Hold” from the fourteen brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $103.36.

Several analysts recently weighed in on AFL shares. Morgan Stanley upped their price target on Aflac from $98.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Barclays cut their price target on Aflac from $98.00 to $95.00 and set an “underweight” rating on the stock in a research note on Friday, February 7th. StockNews.com upgraded Aflac from a “sell” rating to a “hold” rating in a research note on Friday, February 14th. Evercore ISI cut their price target on Aflac from $104.00 to $102.00 and set an “underperform” rating on the stock in a research note on Wednesday, December 4th. Finally, BMO Capital Markets started coverage on Aflac in a research note on Thursday, January 23rd. They issued a “market perform” rating and a $111.00 price target on the stock.

Insider Transactions at Aflac

In other news, Director Joseph L. Moskowitz sold 1,000 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the director now directly owns 25,393 shares in the company, valued at $2,733,048.59. This trade represents a 3.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Charles D. Lake II sold 29,802 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $107.29, for a total value of $3,197,456.58. Following the completion of the transaction, the director now owns 49,962 shares in the company, valued at approximately $5,360,422.98. This trade represents a 37.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,546 shares of company stock worth $5,863,616 in the last ninety days. Insiders own 0.80% of the company’s stock.

Hedge Funds Weigh In On Aflac

Institutional investors have recently bought and sold shares of the stock. Whipplewood Advisors LLC bought a new position in Aflac in the 4th quarter worth $26,000. Darwin Wealth Management LLC bought a new position in Aflac in the 3rd quarter worth $34,000. BankPlus Trust Department bought a new position in Aflac in the 4th quarter worth $34,000. Raelipskie Partnership bought a new position in Aflac in the 3rd quarter worth $38,000. Finally, Curio Wealth LLC bought a new position in Aflac in the 4th quarter worth $36,000. 67.44% of the stock is owned by institutional investors.

Aflac Stock Up 1.1 %

Shares of NYSE:AFL opened at $108.49 on Monday. Aflac has a 52-week low of $79.31 and a 52-week high of $115.50. The firm has a market capitalization of $59.30 billion, a P/E ratio of 11.30, a P/E/G ratio of 3.24 and a beta of 0.93. The stock has a 50 day moving average price of $105.70 and a 200-day moving average price of $107.65. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.08 and a current ratio of 0.10.

Aflac (NYSE:AFL) last announced its earnings results on Wednesday, February 5th. The financial services provider reported $1.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.07). Aflac had a return on equity of 16.20% and a net margin of 28.76%. As a group, equities research analysts anticipate that Aflac will post 6.88 EPS for the current fiscal year.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.